age1
Venture capitalSan Francisco · Pre-Seed–Series A · 9 people tracked
Investment thesis
age1 backs contrarian founders developing therapeutics, tools, and technologies that target aging and age-related disease to extend healthy lifespan. The firm frames the shift from 'sickcare' to healthcare — preventing the onset of age-related disease rather than treating individual conditions — as a transformative moment in medicine. age1 invests at the earliest possible stage, often before any capital has been raised or even before a formal idea exists, and aims to build a pragmatic, rigorous, and optimistic longevity community. It prefers to lead rounds to secure founder-friendly terms and is capitalized to follow on in later rounds. It evolved from the Longevity Fund and a 2018 accelerator into a dedicated firm.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website
What they invest in
from 19 of 24 portfolio companiesBiotech ×19Deep Tech ×8Healthtech ×7AI & Machine Learning ×6Longevity ×5Medical Devices ×4Digital Health ×2
HQs:United States×9
Investments · 24 tracked
founders shown can be your intro pathBiotechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jose Rivera(Executive Officer)Carl Gordon(Director)Jean-Francois Formela(Director)John Leonard(Executive Officer, Director)Rachel Haurwitz(Director)
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases.
AI & Machine LearningBiotechMedical DevicesAustin, US
Adam Freund(Founder & Chief Executive Officer)Remi-Martin Laberge(Founder and Chief Technology Officer)
BoardVineeta Agarwala(Director)
Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.
BiotechDeep TechHealthtech
Matt Krisiloff(CEO)Bianka Seres(President)
Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.
BiotechDigital HealthLongevitySan Francisco, US
Robin Mansukhani(CEO and Co-Founder)inAnil Bhushan(Scientific Founder)inDylan Morris(Director)in
General Control develops multiplexed epigenetic editors—programmable therapies that simultaneously control multiple genes to address complex diseases like Alzheimer's and sarcopenia.
BiotechDeep Tech
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)in
Gordian uses a proprietary in vivo drug discovery platform to identify therapeutic targets and treatments for complex age-related diseases.
AI & Machine LearningBiotechLongevity
Therapies for gastrointestinal and liver disease (NASDAQ: MTCR).
BiotechSan Diego, US
Kristina Burow(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)Richard Heyman(Director)Amir Nashat(Director)Robert Adelman(Director)
BiotechCambridge, US
Jean-Francois Formela(Director)Rick Lundberg(Executive Officer)Alan Crane(Director)David Madden(Director)Marian Nakada(Director)Brian Gallagher(Director)
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevity
Brian Armstrong(Co-founder, Board of Directors)Blake Byers(Director)Jacob Kimmel(Director)Michael Polansky(Executive Officer)
BoardZavain Dar(Director)
Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier.
BiotechHealthtech
Science Corporation develops brain-computer interface and neural engineering technology to restore vision, cognition, and mobility to patients with debilitating conditions.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesAlameda, US
Max Hodak(Chief Executive Officer)
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Frequently asked questions
- What stage does age1 invest at?
- age1 invests at the Pre-Seed, Seed, Series A stages.
- What is age1's typical check size?
- age1 typically writes checks of $500K – $4M.
- What sectors does age1 focus on?
- age1 focuses on Biotech, Healthtech, Longevity.
- Where is age1 located?
- age1 is headquartered in San Francisco, US.
- Does age1 lead rounds?
- Yes, age1 leads investment rounds.
Media · Podcasts & interviews
featuring the teamRoundtable with Alex Colville of AGE1: Revolutionizing Global Healthcare
Longevity Biotechnology Association · Alex Colville
Dr. Alex Colville, Ph.D., Co-Founder & General Partner - age1 - Longevity Biotech Venture Investing
Progress, Potential, and Possibilities · Alex Colville
Dr. Alex Colville, Ph.D. - Co-Founder and General Partner - age1
Progress, Potential, and Possibilities · Alex Colville
Age1’s Alex Colville: “Inventing the anti-ageing pill” - The Times Tech Podcast | Acast
Alex Colville · shows.acast.com
Images
Co-investors · 3
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
Abstract is a San Francisco-based venture capital firm managing $1.8 billion in assets, focused on seed and early-stage investments.
Refactor is a seed-stage venture firm run as a solo capitalist by Zal, backing founders building hard tech companies that address real-world problems.
Firms observed investing alongside age1, from public investor directories. Shared companies are the overlap with age1's recorded portfolio.
Similar investors
Future Positive Capital is an investment firm backing entrepreneurs building companies that address major global challenges and shape more sustainable, preferable futures.
AlleyCorp is a firm of technologists, investors, and entrepreneurs that both builds and invests in transformative companies.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.